Bronchoprotective and anti-inflammatory effect of beclometasone dipropionate plus formoterol HFA fixed combination in asthmatic patients

B. J. O‘Connor, S. Collarini, G. Poli, C. Brindicci, D. Acerbi, P. J. Barnes, B. Leaker (Parma, Italy; London, United Kingdom)

Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Session: Aspects of uncontrolled asthma
Session type: Thematic Poster Session
Number: 1984
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B. J. O‘Connor, S. Collarini, G. Poli, C. Brindicci, D. Acerbi, P. J. Barnes, B. Leaker (Parma, Italy; London, United Kingdom). Bronchoprotective and anti-inflammatory effect of beclometasone dipropionate plus formoterol HFA fixed combination in asthmatic patients. Eur Respir J 2009; 34: Suppl. 53, 1984

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

PK and PD of a new beclomethasone dipropionate and formoterol CFC-free fixed combination
Source: Eur Respir J 2007; 30: Suppl. 51, 358s
Year: 2007

The anti-inflammatory effect of budesonide 800 μg/day via Easyhaler® compared with the same dose of budesonide via Turbuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 337s
Year: 2001

Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002

Dose linearity of beclometasone dipropionate (BDP) in a pMDI BDP plus formoterol fixed combination
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children
Source: Eur Respir J 2005; 26: Suppl. 49, 159s
Year: 2005

Effect of montelukast or salmeterol added to inhaled fluticasone on response to albuterol in children with exercise-induced bronchoconstriction
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009

Comparative clinical study of addition theophylline to low-dose inhaled beclomethasone dipropionate and medium-dose inhaled beclomethasone dipropionate in patients with mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids
Source: Eur Respir J 2002; 19: 182-191
Year: 2002



Pharmacokinetics and pharmacodynamics of a new beclomethasone dipropionate and formoterol CFC-free fixed combination in healthy volunteers
Source: Eur Respir J 2006; 28: Suppl. 50, 667s
Year: 2006

Salmeterol and beclomethasone dipropionate versus higher dose beclomethasone dipropionate in asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Lung deposition of the extrafine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI® in healthy subjects, asthmatic and COPD patients
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma
Source: Eur Respir J 2007; 29: 682-689
Year: 2007



QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Effects of the changing from chlorofluorocarbon (CFC)- beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children
Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Year: 2007


A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone
Source: Eur Respir J 2001; 18: Suppl. 33, 53s
Year: 2001

Protective effect of inhaled beclomethasone dipropionate (BDP) in asthmatic patients with exercise-induced bronchoconstriction (EIB)
Source: Eur Respir J 2002; 20: Suppl. 38, 306s
Year: 2002

Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler®
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012


Airway and systemic effects of hydrofluoroalkane formulations of high dose ciclesonide and fluticasone propionate in moderate persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 583s
Year: 2004

Hydrofluoroalkane beclomethasone dipropionate extra fine aerosol efficacy response at reduced dose compared to other inhaled corticosteroid treatment regimens
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001